Dr. Richert, joins us from the National Multiple Sclerosis Society where he served as Executive Vice President for Research and Clinical Programs for the ...
... the marketing and distribution contract for the oral drug laquinimod, which is developed for treatment of relapsing-remitting multiple sclerosis (RRMS). ...
The most common type of MS is called 'relapsing remitting multiple sclerosis'. This means you have periods without any symptoms, then periods when you get a ...
... somewhat more effective for preventing relapses of multiple sclerosis (MS), as well as slowing damage to the nervous system which occurs with MS. ...
Many multiple sclerosis patients have said the drug dramatically reduces debilitating flare-ups of their symptoms. “Based on the available information, ...
Crain's Detroit Business - Jay Greene - 16 hours ago
... of central nervous systems diseases. Clinical trials are underway for Adeona's Trimesta for the treatment of relapsing-remitting multiple sclerosis.
A new study reveals that multiple sclerosis (MS) patients enrolled in a seven-month disease therapy management (DTM) program show greater adherence to ...
Email this story
